Germany's Medical Cannabis Crackdown Sparks Fierce Political Clash Over Patient Access

Germany's government is debating stricter rules for medical cannabis prescriptions, with deep divisions over how to regulate access. Health Minister Nina Warken (CDU) wants to ban online prescriptions and mail-order deliveries, arguing the current system is too loose. Meanwhile, opposition lawmakers and medical groups are pushing back, warning that tighter controls could limit patient care.

The cabinet's draft law on telemedicine and cannabis faces an uphill battle in parliament. Key sticking points include the future of digital prescriptions and the role of telemedicine. SPD health spokesperson Serdar Yüksel made clear that reversing telemedicine rules is off the table, insisting doctors must retain the freedom to prescribe cannabis as they see fit. He argued that pain varies widely between patients, so treatment should not be restricted by rigid regulations.

Both coalition parties agree on one issue: so-called 'click-through' prescriptions—where patients receive medication in under 30 seconds—must end. Medical associations have already begun cracking down on doctors who guide patients through online questionnaires to secure quick approvals. CDU politician Dr. Thomas Pauls stressed the need to separate medical cannabis from recreational use, particularly when it comes to products ordered online.

France's stricter model has been cited as a possible blueprint. There, medical cannabis flowers are only available through standardised inhalation devices, and prescriptions must come from specially trained physicians after an initial hospital visit. Germany's current system is far more flexible, allowing a wider range of doctors to prescribe individually tailored cannabis treatments without mandatory hospital referrals.

In a bid to find middle ground, the Association of Cannabis Supplying Pharmacies (VCA) proposed pilot schemes. Their suggestion would let certain cannabis products be sold over the counter in pharmacies, easing access while maintaining oversight. But with the draft law lacking broad support, major changes appear unlikely without compromise.

The debate highlights a clash between tighter oversight and patient access. If the current proposal fails, policymakers may need to revisit the rules or explore alternatives like the VCA's pilot projects. For now, digital prescriptions remain unchanged, but the future of online cannabis distribution stays uncertain.